Pharma pivots to personalized treatments as $500B patent cliff looms

Pharmaceutical companies are shifting R&D focus from blockbuster drugs to personalized, gene- and lifestyle-tailored treatments ahead of a $500B patent cliff between 2026-2032. This strategic pivot could reshape disease treatment priorities and healthcare costs, though the commercial viability of such therapies remains uncertain.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works